Released May 14, 2020, after the close
10-Q filed May 14, 2020, 44 days after period end · 0001390478-20-000014
Q1 2020 · 10-Q
Revenue$0.00$0.00 no prior Q1 2019 on fileno prior Q4 2019 on file
Net Income-$4.14M-$4.14M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.66-$0.66 N/M vs Q1 2019no prior Q4 2019 on file
Operating Income-$4,064,000—
Operating Cash Flow-$6,831,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$4.14M | -$4.54M | -$8.00M | -$4.60M |
| EPS Diluted | -$0.66 | -$11.12 | -$1.67 | -$3.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR